The 11th edition of the Association for Accessible Medicines' annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication later this summer.
Some notable facts from the state data:
WASHINGTON, DC (February 19, 2019) – Today’s decision is a victory for patients who depend on a strong national market for generic and biosimilar medicines. Maryland’s law would have allowed one state to dictate prices in the competitive national market for generic medicines that saved patients and taxpayers $265 billion in 2017.
The Association of Marketing and Communication Professionals (AMCP) has given the Association for Accessible Medicines (AAM) Platinum and Gold awards for recent marketing campaigns. The Hermes Creative Awards, administered and judged by AMCP, recognizes creative excellence in traditional and emerging media.
WASHINGTON DC (May 14, 2018) – Tara Ryan joins the Association for Accessible Medicines’ (AAM) State Government Affairs team as Vice President, State Government Affairs, effective today. She reports to Chris Bowlin, Senior Vice President, Government Affairs.
Everyone supports containing skyrocketing prescription drug prices but Connecticut H.B. 5384 will actually just make the problem worse for Connecticut patients and our economy. Generic medicines saved Connecticuters $2.9 billion in the year 2016 alone.
Everyone supports containing skyrocketing prescription drug prices, but H.B. 243 is misguided and would actually make the problem worse for Louisiana patients and our economy. The same bill became law in Maryland but was later found unconstitutional.
WASHINGTON, DC (April 13, 2018) — Today, the United States Court of Appeals for the Fourth Circuit ruled that Maryland’s HB 631 is unconstitutional because it violates the Commerce Clause of the U.S. Constitution. As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce generic drug competition and choice, thus resulting in an overall increase in drug costs due to increased reliance upon more-costly branded medications.
Chester "Chip" Davis, Jr. President and CEO, Association for Accessible Medicines
Everyone supports containing skyrocketing prescription drug prices but SB 1023, sponsored by Sen. Joan Carter Conway (D-Baltimore City), and HB 1194, sponsored by Del. Joseline Pena-Melnyk (D-Anne Arundel & Prince George’s Counties), would actually just make the problem worse for Maryland patients and our economy.
Everyone supports containing skyrocketing prescription drug prices, but H.B. 1179 would actually just make the problem worse for Colorado patients and our economy. The same bill became law in Maryland but was later found unconstitutional.
Everyone supports containing skyrocketing prescription drug prices but HB 4900, sponsored by Rep. Will Guzzardi (D-Chicago), would actually just make the problem worse for Illinois patients. Price gouging– targeted by this bill – is unacceptable. But we must employ sound public policy to both weed out bad apples and enhance a market where they cannot take seed. HB 4900 fails to do either.